{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T04:47:09Z","timestamp":1794804429647,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA188900"],"award-info":[{"award-number":["5R01CA188900"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00262-022-03156-x","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T07:24:29Z","timestamp":1644909869000},"page":"2355-2369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients"],"prefix":"10.1007","volume":"71","author":[{"given":"ANM Nazmul H.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany R.","family":"Emmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Magner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Alqassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Singel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunle","family":"Odunsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Tomasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott I.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Circe","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-7380","authenticated-orcid":false,"given":"Brahm H.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"3156_CR1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, Bohm S, Ahmed AA et al (2015) Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15:668\u2013679","journal-title":"Nat Rev Cancer"},{"key":"3156_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203\u2013213","journal-title":"N Engl J Med"},{"key":"3156_CR3","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538\u201318543","journal-title":"Proc Natl Acad Sci USA"},{"key":"3156_CR4","doi-asserted-by":"publisher","first-page":"15621","DOI":"10.18632\/oncotarget.14919","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Wang J, Chen R, Bai Y, Lu X (2017) The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget 8:15621\u201315631","journal-title":"Oncotarget"},{"key":"3156_CR5","doi-asserted-by":"crossref","unstructured":"Jimenez-Sanchez A, Memon D, Pourpe S et al (2017) Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170:927\u201338 e20","DOI":"10.1016\/j.cell.2017.07.025"},{"key":"3156_CR6","doi-asserted-by":"publisher","first-page":"8900","DOI":"10.1158\/0008-5472.CAN-07-1866","volume":"67","author":"I Kryczek","year":"2007","unstructured":"Kryczek I, Wei S, Zhu G et al (2007) Relationship between B7\u2013H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67:8900\u20138905","journal-title":"Cancer Res"},{"key":"3156_CR7","doi-asserted-by":"publisher","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","volume":"71","author":"N Obermajer","year":"2011","unstructured":"Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P (2011) PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71:7463\u20137470","journal-title":"Cancer Res"},{"key":"3156_CR8","doi-asserted-by":"publisher","first-page":"11310","DOI":"10.18632\/oncotarget.3597","volume":"6","author":"AN Khan","year":"2015","unstructured":"Khan AN, Kolomeyevskaya N, Singel KL et al (2015) Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. Oncotarget 6:11310\u201311326","journal-title":"Oncotarget"},{"key":"3156_CR9","doi-asserted-by":"crossref","unstructured":"Etzerodt A, Moulin M, Doktor TK et al (2020) Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J Exp Med 217(4):e20191869","DOI":"10.1084\/jem.20191869"},{"key":"3156_CR10","doi-asserted-by":"crossref","unstructured":"Xia H, Li S, Li X et al (2020) Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis. JCI Insight 5(18):e141115","DOI":"10.1172\/jci.insight.141115"},{"key":"3156_CR11","doi-asserted-by":"publisher","first-page":"96496","DOI":"10.18632\/oncotarget.20410","volume":"8","author":"YA Lyons","year":"2017","unstructured":"Lyons YA, Pradeep S, Wu SY et al (2017) Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget 8:96496\u201396505","journal-title":"Oncotarget"},{"key":"3156_CR12","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni E, Lemoine J, Vimeux L et al (2018) Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci USA 115:E4041\u2013E4050","journal-title":"Proc Natl Acad Sci USA"},{"key":"3156_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2017.07.007","volume":"147","author":"X Yuan","year":"2017","unstructured":"Yuan X, Zhang J, Li D et al (2017) Prognostic significance of tumor-associated macrophages in ovarian cancer: a meta-analysis. Gynecol Oncol 147:181\u2013187","journal-title":"Gynecol Oncol"},{"key":"3156_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1757-2215-7-19","volume":"7","author":"M Zhang","year":"2014","unstructured":"Zhang M, He Y, Sun X et al (2014) A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res 7:19","journal-title":"J Ovarian Res"},{"key":"3156_CR15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1172\/JCI59643","volume":"122","author":"A Sica","year":"2012","unstructured":"Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787\u2013795","journal-title":"J Clin Invest"},{"key":"3156_CR16","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20080108","volume":"205","author":"T Hagemann","year":"2008","unstructured":"Hagemann T, Lawrence T, McNeish I et al (2008) \u201cRe-educating\u201d tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205:1261\u20131268","journal-title":"J Exp Med"},{"key":"3156_CR17","first-page":"7318","volume":"50","author":"P Allavena","year":"1990","unstructured":"Allavena P, Peccatori F, Maggioni D et al (1990) Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 50:7318\u20137323","journal-title":"Cancer Res"},{"key":"3156_CR18","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1054\/bjoc.1999.1053","volume":"82","author":"GH Windbichler","year":"2000","unstructured":"Windbichler GH, Hausmaninger H, Stummvoll W et al (2000) Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82:1138\u20131144","journal-title":"Br J Cancer"},{"key":"3156_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ygyno.2008.01.005","volume":"109","author":"DS Alberts","year":"2008","unstructured":"Alberts DS, Marth C, Alvarez RD et al (2008) Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin\/paclitaxel versus carboplatin\/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 109:174\u2013181","journal-title":"Gynecol Oncol"},{"key":"3156_CR20","first-page":"59","volume":"15","author":"DF Alonso","year":"1999","unstructured":"Alonso DF, Gabri MR, Guthmann MD, Fainboim L, Gomez DE (1999) A novel hydrophobized GM3 ganglioside\/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma. Int J Oncol 15:59\u201366","journal-title":"Int J Oncol"},{"key":"3156_CR21","first-page":"5165","volume":"56","author":"G Marquina","year":"1996","unstructured":"Marquina G, Waki H, Fernandez LE et al (1996) Gangliosides expressed in human breast cancer. Cancer Res 56:5165\u20135171","journal-title":"Cancer Res"},{"key":"3156_CR22","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1016\/j.vaccine.2004.02.010","volume":"22","author":"C Mesa","year":"2004","unstructured":"Mesa C, De Leon J, Rigley K, Fernandez LE (2004) Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 22:3045\u20133052","journal-title":"Vaccine"},{"key":"3156_CR23","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1016\/j.vaccine.2005.08.111","volume":"24","author":"C Mesa","year":"2006","unstructured":"Mesa C, de Leon J, Fernandez LE (2006) Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 24:2692\u20132699","journal-title":"Vaccine"},{"key":"3156_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4049\/jimmunol.1001465","volume":"186","author":"A Fernandez","year":"2011","unstructured":"Fernandez A, Mesa C, Marigo I et al (2011) Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol 186:264\u2013274","journal-title":"J Immunol"},{"key":"3156_CR25","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.22085","volume":"119","author":"BS Ramirez","year":"2006","unstructured":"Ramirez BS, Pestana ES, Hidalgo GG et al (2006) Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer 119:2190\u20132199","journal-title":"Int J Cancer"},{"key":"3156_CR26","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1016\/j.vaccine.2019.05.060","volume":"37","author":"M Granadillo","year":"2019","unstructured":"Granadillo M, Batte A, Alfonso AB et al (2019) Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate. Vaccine 37:3957\u20133960","journal-title":"Vaccine"},{"key":"3156_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3389\/fphar.2017.00263","volume":"8","author":"I Caballero","year":"2017","unstructured":"Caballero I, Aira LE, Lavastida A et al (2017) Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: a dose-escalation phase I study trial. Front Pharmacol 8:263","journal-title":"Front Pharmacol"},{"key":"3156_CR28","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1016\/j.vaccine.2017.05.020","volume":"35","author":"Y Morera","year":"2017","unstructured":"Morera Y, Sanchez J, Bequet-Romero M et al (2017) Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. Vaccine 35:3582\u20133590","journal-title":"Vaccine"},{"key":"3156_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10456-008-9121-5","volume":"11","author":"Y Morera","year":"2008","unstructured":"Morera Y, Bequet-Romero M, Ayala M et al (2008) Anti-tumoral effect of active immunotherapy in C57BL\/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 11:381\u2013393","journal-title":"Angiogenesis"},{"key":"3156_CR30","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1016\/j.vaccine.2005.07.049","volume":"23","author":"I Torrens","year":"2005","unstructured":"Torrens I, Mendoza O, Batte A et al (2005) Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine 23:5768\u20135774","journal-title":"Vaccine"},{"key":"3156_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s42003-019-0718-6","volume":"2","author":"A Detavernier","year":"2019","unstructured":"Detavernier A, Azouz A, Shehade H et al (2019) Monocytes undergo multi-step differentiation in mice during oral infection by Toxoplasma gondii. Commun Biol 2:472","journal-title":"Commun Biol"},{"key":"3156_CR32","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1084\/jem.20182024","volume":"216","author":"N Zhang","year":"2019","unstructured":"Zhang N, Czepielewski RS, Jarjour NN et al (2019) Expression of factor V by resident macrophages boosts host defense in the peritoneal cavity. J Exp Med 216:1291\u20131300","journal-title":"J Exp Med"},{"key":"3156_CR33","doi-asserted-by":"crossref","unstructured":"Godoy HE, Khan AN, Vethanayagam RR et al (2013) Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. PLoS ONE 8:e69631","DOI":"10.1371\/journal.pone.0069631"},{"key":"3156_CR34","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1084\/jem.20050930","volume":"203","author":"I Kryczek","year":"2006","unstructured":"Kryczek I, Zou L, Rodriguez P et al (2006) B7\u2013H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203:871\u2013881","journal-title":"J Exp Med"},{"key":"3156_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41416-018-0339-8","volume":"120","author":"KL Singel","year":"2019","unstructured":"Singel KL, Grzankowski KS, Khan A et al (2019) Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. Br J Cancer 120:207\u2013217","journal-title":"Br J Cancer"},{"key":"3156_CR36","doi-asserted-by":"crossref","unstructured":"Singel KL, Emmons TR, Khan ANH et al (2019) Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight 4(5):e122311","DOI":"10.1172\/jci.insight.122311"},{"key":"3156_CR37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1158\/2326-6066.CIR-20-0922","volume":"9","author":"TR Emmons","year":"2021","unstructured":"Emmons TR, Giridharan T, Singel KL et al (2021) Mechanisms driving neutrophil-induced T-cell immunoparalysis in ovarian cancer. Cancer Immunol Res 9:790\u2013810","journal-title":"Cancer Immunol Res"},{"key":"3156_CR38","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ncb3371","volume":"18","author":"C Baer","year":"2016","unstructured":"Baer C, Squadrito ML, Laoui D et al (2016) Suppression of microRNA activity amplifies IFN-gamma-induced macrophage activation and promotes anti-tumour immunity. Nat Cell Biol 18:790\u2013802","journal-title":"Nat Cell Biol"},{"key":"3156_CR39","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1038\/onc.2014.294","volume":"34","author":"H Mathsyaraja","year":"2015","unstructured":"Mathsyaraja H, Thies K, Taffany DA et al (2015) CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Oncogene 34:3651\u20133661","journal-title":"Oncogene"},{"key":"3156_CR40","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1073\/pnas.0915000107","volume":"107","author":"EE Ghosn","year":"2010","unstructured":"Ghosn EE, Cassado AA, Govoni GR et al (2010) Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci USA 107:2568\u20132573","journal-title":"Proc Natl Acad Sci USA"},{"key":"3156_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/jlb.57.3.361","volume":"57","author":"MW Barth","year":"1995","unstructured":"Barth MW, Hendrzak JA, Melnicoff MJ, Morahan PS (1995) Review of the macrophage disappearance reaction. J Leukoc Biol 57:361\u2013367","journal-title":"J Leukoc Biol"},{"key":"3156_CR42","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.cell.2014.04.016","volume":"157","author":"Y Okabe","year":"2014","unstructured":"Okabe Y, Medzhitov R (2014) Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157:832\u2013844","journal-title":"Cell"},{"key":"3156_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3892\/ol.2020.12410","volume":"21","author":"H Zhou","year":"2021","unstructured":"Zhou H, Jiang M, Yuan H, Ni W, Tai G (2021) Dual roles of myeloid-derived suppressor cells induced by Toll-like receptor signaling in cancer. Oncol Lett 21:149","journal-title":"Oncol Lett"},{"key":"3156_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ijc.2910510109","volume":"51","author":"N Colombo","year":"1992","unstructured":"Colombo N, Peccatori F, Paganin C et al (1992) Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 51:42\u201346","journal-title":"Int J Cancer"},{"key":"3156_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2249.2006.03297.x","volume":"147","author":"C Venier","year":"2007","unstructured":"Venier C, Guthmann MD, Fernandez LE, Fainboim L (2007) Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant. Clin Exp Immunol 147:379\u2013388","journal-title":"Clin Exp Immunol"},{"key":"3156_CR46","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/ATVBAHA.116.304054","volume":"36","author":"YP Zhu","year":"2016","unstructured":"Zhu YP, Thomas GD, Hedrick CC (2016) 2014 Jeffrey M. Hoeg award lecture: transcriptional control of monocyte development. Arterioscler Thromb Vasc Biol 36:1722\u20131733","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3156_CR47","doi-asserted-by":"publisher","first-page":"31930","DOI":"10.1074\/jbc.M110.101709","volume":"285","author":"W Coley","year":"2010","unstructured":"Coley W, Van Duyne R, Carpio L et al (2010) Absence of DICER in monocytes and its regulation by HIV-1. J Biol Chem 285:31930\u201331943","journal-title":"J Biol Chem"},{"key":"3156_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-2199-8-63","volume":"8","author":"Z Klase","year":"2007","unstructured":"Klase Z, Kale P, Winograd R et al (2007) HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol 8:63","journal-title":"BMC Mol Biol"},{"key":"3156_CR49","doi-asserted-by":"publisher","first-page":"28433","DOI":"10.1074\/jbc.M114.599316","volume":"289","author":"RL Eigsti","year":"2014","unstructured":"Eigsti RL, Sudan B, Wilson ME, Graff JW (2014) Regulation of activation-associated microRNA accumulation rates during monocyte-to-macrophage differentiation. J Biol Chem 289:28433\u201328447","journal-title":"J Biol Chem"},{"key":"3156_CR50","doi-asserted-by":"publisher","first-page":"12823","DOI":"10.1074\/jbc.M114.565473","volume":"289","author":"TJ Gross","year":"2014","unstructured":"Gross TJ, Powers LS, Boudreau RL et al (2014) A microRNA processing defect in smokers\u2019 macrophages is linked to SUMOylation of the endonuclease DICER. J Biol Chem 289:12823\u201312834","journal-title":"J Biol Chem"},{"key":"3156_CR51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0264-410X(99)00219-4","volume":"18","author":"F Estevez","year":"1999","unstructured":"Estevez F, Carr A, Solorzano L et al (1999) Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 18:190\u2013197","journal-title":"Vaccine"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03156-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03156-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03156-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T03:04:12Z","timestamp":1666494252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03156-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3156"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03156-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All mice were maintained under specific pathogen free conditions at the animal care facility at Roswell Park Comprehensive Cancer Center (Buffalo, NY) and used in compliance with all relevant laws and institutional guidelines under a protocol approved by the Roswell Park Animal Care and Use Committee. This study was approved by the Institutional Review Board of Roswell Park Comprehensive Cancer Center (Buffalo, NY) and was following federal and state requirements. All studies were conducted in compliance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"All participants gave written informed consent prior to inclusion in the study (protocols I 215512 and I 188310).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}